264 related articles for article (PubMed ID: 30893872)
1. Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer's Disease.
Pradeepkiran JA; Reddy PH
Cells; 2019 Mar; 8(3):. PubMed ID: 30893872
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.
Pradeepkiran JA; Munikumar M; Reddy AP; Reddy PH
Hum Mol Genet; 2021 Dec; 31(2):244-261. PubMed ID: 34432046
[TBL] [Abstract][Full Text] [Related]
3. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
Ahmad W; Shabbiri K; Ahmad I
Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
Pradeepkiran JA; Reddy AP; Reddy PH
Drug Discov Today; 2019 Feb; 24(2):616-623. PubMed ID: 30453058
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments.
Alonso A; Zaidi T; Novak M; Grundke-Iqbal I; Iqbal K
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6923-8. PubMed ID: 11381127
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
[TBL] [Abstract][Full Text] [Related]
7. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
8. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease.
Huang HC; Jiang ZF
J Alzheimers Dis; 2009; 16(1):15-27. PubMed ID: 19158417
[TBL] [Abstract][Full Text] [Related]
9. Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid.
Yao J; Gao X; Sun W; Yao T; Shi S; Ji L
Biochemistry; 2013 Mar; 52(11):1893-902. PubMed ID: 23442089
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
12. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease.
Hernandes-Alejandro M; Montaño S; Harrington CR; Wischik CM; Salas-Casas A; Cortes-Reynosa P; Pérez Salazar E; Cazares-Apatiga J; Apatiga-Perez R; Ontiveros Torres MÁ; Perry G; Pacheco-Herrero M; Luna-Muñoz J
J Alzheimers Dis; 2020; 76(2):553-569. PubMed ID: 32538846
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.
Eidenmüller J; Fath T; Hellwig A; Reed J; Sontag E; Brandt R
Biochemistry; 2000 Oct; 39(43):13166-75. PubMed ID: 11052669
[TBL] [Abstract][Full Text] [Related]
16. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
17. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
Pinsetta FR; Taft CA; de Paula da Silva CH
J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842
[TBL] [Abstract][Full Text] [Related]
18. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease.
Kumar P; Jha NK; Jha SK; Ramani K; Ambasta RK
J Alzheimers Dis; 2015; 43(2):341-61. PubMed ID: 25096626
[TBL] [Abstract][Full Text] [Related]
19. Molecules of the quinoline family block tau self-aggregation: implications toward a therapeutic approach for Alzheimer's disease.
Navarrete LP; Guzmán L; San Martín A; Astudillo-Saavedra L; Maccioni RB
J Alzheimers Dis; 2012; 29(1):79-88. PubMed ID: 22232002
[TBL] [Abstract][Full Text] [Related]
20. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
